Immix Biopharma Inc (IMMX): Immix Biopharma Announces 72-Patient NXC...

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

Immix Biopharma Inc (IMMX)

Reply Private New

Keep Last Read

Next 10 Prev Next

Send PM Follow Ignore

Followers	47
Posts	2202
Boards Moderated	0
Alias Born	10/04/2013

Re: vegasandre post# 197

Monday, 10/02/2023 1:21:46 PM

Monday, October 02, 2023 1:21:46 PM

Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

Yahoo Finance

Yahoo Finance

Sign in

?

Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

Immix Biopharma, Inc.

Mon, Oct 2, 2023, 5:06 AM PDT11 min read

IMMX+20.91%

Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy. Median progression free survival (mPFS) was 12.9 months as of the July 17, 2023 data cut-off

90% overall response rate observed in relapsed/refractory multiple myeloma at the therapeutic dose including patients with, and without prior BCMA-targeted therapy

Class-Leading Response Rate in BCMA-exposed patients (frequently excluded from BCMA CAR-T clinical trials) has the potential to meet an important market need

ImmixBio plans to submit a BLA for FDA approval in multiple myeloma once 100 patients are treated with NXC-201

The expected primary endpoints for NXC-201 in relapsed/refractory multiple myeloma are overall response rate and duration of response

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
3M
6M
1Y
5Y

Detailed Quote

Recent IMMX News

Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 09:27:35 PM
Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 05/20/2024 09:27:11 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 09:25:52 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 09:25:48 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 09:25:38 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 09:25:35 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2024 01:29:40 AM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2024 01:28:17 AM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:27:31 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/07/2024 10:15:34 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 02:09:52 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/05/2024 09:38:39 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 09:37:06 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2023 11:25:25 PM
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing • InvestorsHub NewsWire • 11/28/2023 03:48:59 PM
Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 09/25/2023 08:15:53 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2023 11:03:32 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/15/2023 10:27:44 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2023 08:58:37 PM
Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 08/30/2023 08:15:02 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/23/2023 08:28:40 PM

More IMMX News

InvestorsHub NewsWire

"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM

North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM

Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM

Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM

VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM

ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM

Start posting your company's news

Only $200 per official company press release!

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow